Capsaicin

Generic Name: Capsaicin

Brand Names: Capzasin Quick Relief, Capzasin-HP, Castiva Warming, Dendracin Neurodendraxcin, Lidopro, Medi-derm, Medi-derm With Lidocaine, Medrox, Qutenza, Rematex, Xoten-C, Zostrix

Drug Type: Small Molecule

Chemical Formula: C_₁₈H_₂₇NO_₃

CAS Number: 404-86-4

Unique Ingredient Identifier: S07O44R1ZM

Background: Capsaicin is most often used as a topical analgesic and exists in many formulations of cream, liquid, and patch preparations of various strengths; however, it may also be found in some dietary supplements. Capsaicin is a naturally-occurring botanical irritant in chili peppers, synthetically derived for pharmaceutical formulations. The most recent capsaicin FDA approval was Qutenza, an 8% capsaicin patch dermal-delivery system, indicated for neuropathic pain associated with post-herpetic neuralgia.

Indication: The capsaicin 8% patch is indicated in the treatment of neuropathic pain associated with post-herpetic neuralgia. There are multiple topical capsaicin formulations available, including creams and solutions, indicated for temporary analgesia in muscle and join pain as well as neuropathic pain.

Associated Conditions: Back Pain Lower Back, Back pain, Bursitis, Contusions, Inflammatory Reaction caused by Rheumatism, Muscle Cramps, Musculoskeletal Pain, Neuropathic Pain, Osteoarthritis (OA), Pain caused by Rheumatism, Periarthritis, Soft Tissue Injury, Tendinitis, Acute nonspecific tenosynovitis, Articular inflammation

Clinical Trials

A Study to Evaluate Laser Speckle Contrast Imaging to Assess Changes in Chemical Agent-Induced Skin Blood Flow in Healthy Participants (MK-0000-420)

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Allyl Isothiocyanate (AITC)
Drug: Capsaicin
Other: Vehicle for AITC
Other: Vehicle for Capsaicin

First Posted Date: 2025-02-05

Last Posted Date: 2025-02-05

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 12

Registration Number: NCT06809569

Locations: 🇧🇪
Center for Clinical Pharmacology (CCP) (Site 0001), Leuven, Vlaams-Brabant, Belgium

Serratus Plane Block (SPB) Versus Capsaïcine Versus Botox-A for Chronic Neuropathic Pain in Post-mastectomy Syndrome

Phase 2

Not yet recruiting

Conditions: Post-Mastectomy Neuropathic Pain Syndrome

Interventions: Drug: Capsaicin 8% Patch
Procedure: Serratus Plane Block
Procedure: Botulinum Toxin A

First Posted Date: 2025-02-04

Last Posted Date: 2025-02-06

Lead Sponsor: Centre Oscar Lambret

Target Recruit Count: 123

Registration Number: NCT06807164

Locations: 🇫🇷
Centre Oscar Lambret, Lille, Hauts-de-France, France

Exploring the Benefit of Topical Capsaicin in Treating Pain From Chemo-induced Peripheral Neuropathy: a Longitudinal Single Center Pilot Study

Early Phase 1

Not yet recruiting

Conditions: Peripheral Neuropathy Due to Chemotherapy

Interventions: Drug: Qutenza Patch

First Posted Date: 2024-12-20

Last Posted Date: 2025-01-31

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 20

Registration Number: NCT06744816

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

Qutenza 8% Capsaicin Topical System for the Treatment of Neuropathic Axial Lower Back Pain and Lumbosacral Radiculopathy

Conditions: Lower Back Pain
Lumbosacral Radiculopathy

Interventions: Drug: Qutenza® 8% Capsaicin Topical System

First Posted Date: 2024-08-06

Last Posted Date: 2025-03-19

Lead Sponsor: Medical University of South Carolina

Target Recruit Count: 50

Registration Number: NCT06540456

Locations: 🇺🇸
MUSC Health Nexton Medical Park, Summerville, South Carolina, United States

Observational Study to Evaluate the Efficacy of Sustained QUTENZA® Use in Painful Diabetic Peripheral Neuropathy

Not yet recruiting

Conditions: Peripheral Diabetic Neuropathy
Painful Diabetic Neuropathy

Interventions: Drug: Capsaicin 8%

First Posted Date: 2024-07-10

Last Posted Date: 2025-03-26

Lead Sponsor: Averitas Pharma, Inc.

Target Recruit Count: 150

Registration Number: NCT06495424

Locations: 🇺🇸
Celéri Health, Inc, Conshohocken, Pennsylvania, United States
🇺🇸
Clinical Research Strategies, LLC, Wexford, Pennsylvania, United States

Capsaicin in Digital Osteoarthritis Versus Control

Phase 4

Recruiting

Conditions: Osteoarthritis Hand
Neuropathic Pain

Interventions: Drug: Capsaicine low dose 0.04 %
Drug: Capsaicin 179 Mg Cutaneous Patch

First Posted Date: 2024-06-06

Last Posted Date: 2025-03-13

Lead Sponsor: University Hospital, Clermont-Ferrand

Target Recruit Count: 120

Registration Number: NCT06444919

Locations: 🇫🇷
HCL Hôpital Edouard Herriot, Lyon, France
🇫🇷
AP-HP Hôpital Saint-Antoine, Paris, France
🇫🇷
CHU de Saint-Etienne, Saint-Étienne, France

and more 1 locations

Study Evaluating the Analgesic Efficacy of Capsaicin 8% Patches in Chronic Coccygodynia.

Phase 3

Recruiting

Conditions: Coccyx Disorder
Neuropathic Pain
Coccygodynia

Interventions: Drug: Capsaicin low concentration patch (capsaicin 0,04%, 3,2 mg/cm2)
Drug: Capsaicin 179 Mg Cutaneous Patch

First Posted Date: 2023-09-05

Last Posted Date: 2024-07-26

Lead Sponsor: Nantes University Hospital

Target Recruit Count: 188

Registration Number: NCT06023706

Locations: 🇫🇷
Confluent Private Hospital Centre, Nantes, France
🇫🇷
Vendée Departmental Hospital, La Roche-sur-Yon, France
🇫🇷
Brest University Hospital, Brest, France

and more 3 locations